SAN FRANCISCO—Active surveillance of small renal masses (SRMs) may be an appropriate approach for many patients, especially older individuals and those with comorbidities that would complicate treatment or reduce life expectancy, according to Michael Jewett, MD, of Princess Margaret Hospital and the University of Toronto.

SAN FRANCISCO—Chemotherapy is associated with a significantly decreased risk of death from prostate cancer (PCa) among elderly men with Stage IV prostate cancer treated with androgen deprivation therapy (ADT), new findings suggest.

SAN FRANCISCO—Obesity is associated with higher positive surgical margin (PSM) rates after robotic-assisted laparoscopic prostatectomy (RALP), a study found.

SAN FRANCISCO—Cumulative mortality from prostate cancer 15 years after radical prostatectomy is six times lower than death from other causes, according to study findings presented here at the Genitourinary Cancers Symposium. Among men older than 65 years at the time of surgery, cumulative 15-year mortality is 10 times lower.

SAN FRANCISCO—Skeletal-related events (SREs) in patients with metastatic hormone-refractory prostate cancer (mHRPC) are mostly due to bony metastatic disease and not decreased bone mineral density (BMD), according to British researchers.

SAN FRANCISCO—Radical prostatectomy (RP) is associated with improved overall survival compared with radiation therapy in men with clinically localized prostate cancer, data suggest.

SAN FRANCISCO—Alcohol consumption may be associated with an increased risk of prostate cancer in African-American men, according to researchers.

SAN FRANCISCO—A new urine test based on a highly specific gene-fusion biomarker may accurately predict the presence of clinically significant prostate cancers at biopsy and radical prostatectomy, according to findings presented here at the Genitourinary Cancers Symposium.

SAN FRANCISCO—The prostate cancer gene 3 (PCA3) molecular urine test is more accurate than the PSA test in predicting outcomes of repeat biopsies, new findings confirm.

SAN FRANCISCO—PSA doubling time (PSADT) is the most important predictor of 15-year overall survival among men who experience biochemical recurrence after radical prostatectomy for prostate cancer, according to a study.